RhumbLine Advisers
OMGA

RhumbLine Advisers’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

RhumbLine Advisers’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,915
Closed -$6.03K – 4364
2024
Q2 		$6.03K Sell
2,915
-19,424
-87% -$45.8K ﹤0.01% 4054
2024
Q1 		$81.5K Buy
22,339
+743
+3% +$2.85K ﹤0.01% 3501
2023
Q4 		$65K Sell
21,596
-1,341
-6% -$2.72K ﹤0.01% 3567
2023
Q3 		$49.3K Buy
22,937
+2,796
+14% +$11.2K ﹤0.01% 3644
2023
Q2 		$113K Buy
+20,141
New +$158K ﹤0.01% 3477
2022
Q2 		– Sell
-15,329
Closed -$96K – 3260
2022
Q1 		$96K Buy
+15,329
New +$156K ﹤0.01% 2894

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's OMGA Position: Q3 2024 in Review

RhumbLine Advisers sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q3 2024, closing a stake of 2,915 shares — an estimated $6.03K sold.

RhumbLine Advisers first reported a position in OMGA in Q1 2022 and held it in 6 quarters. The position peaked at $113K in Q2 2023. 54 funds tracked by Wall St. Rank hold OMGA as of Q3 2024.

  • RhumbLine Advisers reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 2,915 Omega Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $6.03K.
  • RhumbLine Advisers first reported a position in Omega Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
  • RhumbLine Advisers's Omega Therapeutics, Inc. Common Stock position peaked at $113K in Q2 2023.
  • 54 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.